These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 19261963

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Managing patients treated with bevacizumab combination therapy.
    Gordon MS, Cunningham D.
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [Abstract] [Full Text] [Related]

  • 5. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H, Saini S.
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Managing adverse events in the use of bevacizumab and chemotherapy.
    Blowers E, Hall K.
    Br J Nurs; 2006 Oct; 18(6):351-6, 358. PubMed ID: 19329899
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H.
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [Abstract] [Full Text] [Related]

  • 14. Managing bevacizumab-related toxicities in patients with colorectal cancer.
    Saif MW.
    J Support Oncol; 2009 Sep; 7(6):245-51. PubMed ID: 20380333
    [No Abstract] [Full Text] [Related]

  • 15. Incidence and management of bevacizumab-related toxicities in colorectal cancer.
    Saif MW, Mehra R.
    Expert Opin Drug Saf; 2006 Jul; 5(4):553-66. PubMed ID: 16774493
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study.
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH, Gootenberg J, Keegan P, Pazdur R.
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.